IP Library Granted Patent US 9,340,501
Granted Patent B2
US 9,340,501 · App. 14/394,902 · Granted May 17, 2016

Marinopyrrole derivatives as anticancer agents

Inventors: Rongshi Li (Tampa, FL); Said M. Sebti (Tampa, FL); Yan Liu (Tampa, FL)
Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
C07D207/34A61K31/4025A61K45/06A61N5/10C07D207/335C07D403/04A61N2005/1098
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,340,501
App. No.
14/394,902
Granted
May 17, 2016
Kind
B2
Abstract

Marinopyrrole derivatives and methods for their synthesis and use are described herein. The methods of using the compounds include treating and preventing cancer.

Claims (33)

1. A compound of the following structure:

or a pharmaceutically acceptable salt or prodrug thereof, wherein:

R 1 , R 2 , R 3 , and R 4 , are each independently selected from hydrogen, halogen, hydroxyl, cyano, nitro, substituted or unsubstituted amino, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted heteroalkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heteroalkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkoxyl, substituted or unsubstituted aryloxyl, and substituted or unsubstituted carboxyl;

each R 11 , R 12 , R 13 , and R 14 are F, Cl, Br, or I; and

R 5 and R 6 are each selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, and monovalent cation, and

wherein at least one of R 3 and R 4 is a halogen.

2. The compound of claim 1 , wherein at least one of R 3 and R 4 is Cl.

3. The compound of claim 1 , wherein R 11 , R 12 , R 13 , and R 14 are each Cl.

4. The compound of claim 1 , wherein the compound is

5. The compound of claim 1 , wherein the compound is

6. The compound of claim 1 , wherein the compound is:

7. A compound of the following structure:

or a pharmaceutically acceptable salt or prodrug thereof, wherein:

R 1 , R 2 , R 3 , R 4 , R 11 , R 12 , R 13 , R 14 , and R 15 are each independently selected from hydrogen, halogen, hydroxyl, cyano, nitro, substituted or unsubstituted amino, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted heteroalkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heteroalkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkoxyl, substituted or unsubstituted aryloxyl, and substituted or unsubstituted carboxyl;

R 5 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or a monovalent cation; and

X is hydroxyl, substituted or unsubstituted alkoxyl, or substituted or unsubstituted amino,

wherein if R 1 , R 2 , R 3 , R 4 , R 5 , and R 15 are H and R 11 , R 12 , R 13 , and R 14 , are Cl, then X is other than OEt.

8. A composition, comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

9. A method of treating or preventing cancer in a subject, comprising administering to the subject an effective amount of a compound claim 1 .

10. A method of treating or preventing cancer in a subject, comprising administering to the subject an effective amount of a compound selected from the group consisting of:

11. The method of claim 9 , wherein the cancer is selected from the group consisting of bladder cancer, brain cancer, breast cancer, colorectal cancer, cervical cancer, gastrointestinal cancer, genitourinary cancer, head and neck cancer, lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, renal cancer, skin cancer, and testicular cancer.

12. The method of claim 9 , further comprising administering a second compound or composition, wherein the second compound or composition includes an anticancer agent.

13. The method of claim 9 , further comprising administering an effective amount of ionizing radiation to the subject.

14. A method of killing a tumor cell in a subject, comprising:

contacting the tumor cell with an effective amount of a compound claim 1 .

15. A method of killing a tumor cell in a subject, comprising:

contacting the tumor cell with an effective amount of a compound selected from the group consisting of:

16. The method of claim 14 , further comprising contacting the tumor cell with a second compound or composition, wherein the second compound or composition includes an anticancer agent.

17. The method of claim 14 , wherein the tumor cell is a Mcl-1 dependent cell.

18. The method of claim 14 , further comprising irradiating the tumor cell with an effective amount of ionizing radiation.

19. A method of radiotherapy of a tumor, comprising:

contacting the tumor with an effective amount of a compound or composition of claim 1 ; and

irradiating the tumor with an effective amount of ionizing radiation.

Assignments (2)
CONFIRMATORY LICENSE Recorded Nov 14, 2022
From: H. LEE MOFFITT CANCER CET & RES INST
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 061933/0785 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 4, 2016
From: LI, RONGSHI; SEBTI, SAID M.; LIU, YAN
To: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
Reel/Frame 038179/0574 →
Continuity (3)
Provisional Application 61624792 · Apr 16, 2012
Provisional Application 61624758 · Apr 16, 2012
Related Publication 20150080632A1 · Mar 19, 2015